Berin M Cecilia
Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
Curr Pediatr Rep. 2014 Jun 1;2(2):119-126. doi: 10.1007/s40124-014-0041-0.
Food allergy is prevalent, affecting approximately 4-8% of children. There is no currently approved treatment for food allergy, and while strict allergen avoidance is recommended it is difficult to achieve and therefore accidental exposures and reactions are common. There is an urgent need for the development of therapeutic approaches that will improve the health and quality of life of children with food allergy. The majority of current clinical research focus is on specific food allergen immunotherapy through oral, sublingual, or epicutaneous routes. Pre-clinical research has focused on making improvements to the safety and efficacy of allergen immunotherapy through modifications of allergen structure and addition of immuno-modulatory factors. The number of novel therapeutics for food allergy reaching the level of clinical trials remains disappointingly low, and there is a need for an expansion of pre-clinical research to provide safe, practical and novel approaches to the treatment of food allergy.
食物过敏很常见，约4-8%的儿童受其影响。目前尚无获批的食物过敏治疗方法，虽然建议严格避免接触过敏原，但这很难做到，因此意外接触和过敏反应很常见。迫切需要开发治疗方法，以改善食物过敏儿童的健康和生活质量。目前大多数临床研究重点是通过口服、舌下或经皮途径进行特定食物过敏原免疫疗法。临床前研究致力于通过改变过敏原结构和添加免疫调节因子来提高过敏原免疫疗法的安全性和有效性。进入临床试验阶段的食物过敏新型疗法数量仍然少得令人失望，需要扩大临床前研究，以提供安全、实用且新颖的食物过敏治疗方法。
